ADMA Biologics, Inc. 8-K Report: Key Insights on Recent Developments (Jan 13, 2025)

Based on the provided section of the financial report in XBRL format, here are the key insights and information extracted:

1. Company Information:

• Company Name: ADMA Biologics, Inc.
• CIK: 0001368514
• Incorporation State: Delaware (DE)
• SEC File Number: 001-36728
• EIN: 56-2590442
• Address: 465 State Route 17, Ramsey, NJ 07446
• Phone Number: 201-478-5552

2. Filing Type:

• Form: 8-K (Current Report)
• Filing Date: January 13, 2025

3. Stock Information:

• Stock Exchange: NASDAQ
• Type of Stock: Common Stock

4. Reporting Period:

• Start Date: January 13, 2025
• End Date: January 13, 2025

5. Miscellaneous:

• The report is structured in XBRL format, which is standard for SEC filings, allowing for easier data extraction and analysis.

Insights:

• The filing indicates that ADMA Biologics, Inc. is reporting significant information on a specific date (January 13, 2025), which may suggest an important event or change in the company's operations or financial status that necessitated an 8-K filing.
• As a current report, it is likely to contain timely information that could affect the stock price and investor decisions.
• The inclusion of a CIK identifier confirms that this is an official SEC filing, ensuring credibility and compliance with regulatory standards.

Conclusion:

It is important to follow up on the specific details included in the 8-K report filed by ADMA Biologics, Inc. on January 13, 2025, as it could provide insights into recent developments, risk factors, or strategic changes relevant to investors and stakeholders.